Hevascol (Ethyl Esters Of Iodised Fatty Acids From Poppyseed Oil)

Hevascol is listed for investigational or off‑label clinical contexts where modulation of vascular or lymphatic function is considered. Its exact therapeutic indications are not formally established, and use is typically guided by specialist assessment.

• Investigational use in experimental vascular remodeling studies
• Research applications involving lymphatic system modulation
• Potential adjunct in clinical trials assessing microcirculatory support
• Use under compassionate access programs where standard therapies are unavailable
• Evaluation in specialized centers for rare vascular disorders

• Ethyl esters of iodised fatty acids from poppyseed oil are thought to integrate into cell membrane phospholipids, altering lipid composition and influencing membrane fluidity. This may affect signaling pathways related to endothelial function and lymphatic vessel contractility, potentially modulating vascular tone and lymph flow without direct receptor binding. The precise biochemical interactions remain under investigation.

Adverse reactions to Hevascol have been reported in clinical observations and post‑marketing surveillance. They are categorized by frequency and severity.

Common

• Localized pain or discomfort at the injection site
• Mild erythema or swelling
• Transient headache
• Nausea or mild gastrointestinal upset
• Temporary dizziness

Serious

• Acute arterial thrombosis
• Severe allergic reaction (anaphylaxis)
• Persistent hypotension
• Vascular occlusion leading to tissue ischemia
• Lymphatic fistula formation

Hevascol should be used with caution and under professional supervision. Important safety considerations include:

• Verify patient history for bleeding disorders or anticoagulant therapy
• Assess for known hypersensitivity to poppyseed derivatives
• Monitor cardiovascular status during and after intra‑arterial administration
• Use imaging guidance to minimize inadvertent vessel injury
• Avoid use in pregnant or lactating individuals unless benefits outweigh risks
• Ensure appropriate sterile technique to reduce infection risk
• Document informed consent for off‑label or investigational use

Potential drug interactions with Hevascol are not fully characterized, but theoretical considerations suggest caution with certain agents.

Avoid

• Concurrent use of potent anticoagulants (e.g., warfarin, direct oral anticoagulants) due to increased bleeding risk
• High‑dose aspirin or non‑steroidal anti‑inflammatory drugs that may exacerbate vascular irritation

Use with caution

• Vasodilators (e.g., nitroglycerin) that could amplify hypotensive effects
• Immunosuppressants that may alter inflammatory response at the injection site
• Lipid‑lowering agents that could influence fatty acid metabolism
• Other investigational vascular agents administered via the same route